What is William Blair’s Forecast for IPSC FY2024 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC) – Research analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Century Therapeutics in a report released on Tuesday, November 5th. William Blair analyst S. Corwin now expects that the company will post earnings of ($1.64) per share for the year, up from their previous estimate of ($1.88). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.80) per share. William Blair also issued estimates for Century Therapeutics’ Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS and FY2025 earnings at ($1.81) EPS.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. The business had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. During the same quarter in the previous year, the company earned ($0.55) EPS.

IPSC has been the topic of a number of other research reports. HC Wainwright reduced their target price on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday. Chardan Capital reduced their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Rodman & Renshaw initiated coverage on Century Therapeutics in a report on Thursday, August 8th. They set a “buy” rating and a $6.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $11.60.

Century Therapeutics Price Performance

Shares of NASDAQ:IPSC opened at $1.46 on Friday. Century Therapeutics has a 12 month low of $1.14 and a 12 month high of $5.51. The business’s 50 day simple moving average is $1.52 and its 200-day simple moving average is $2.24. The firm has a market capitalization of $123.69 million, a price-to-earnings ratio of -0.79 and a beta of 1.41.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. lifted its stake in shares of Century Therapeutics by 191.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company’s stock valued at $1,229,000 after purchasing an additional 192,915 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Century Therapeutics by 110.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after purchasing an additional 78,088 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares during the period. Rhumbline Advisers boosted its position in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after acquiring an additional 18,828 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics during the 3rd quarter valued at about $27,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.